Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 16, 2026, 10:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Colorectal Disorders Clear all
Completed Not applicable Interventional

Computerized Tomographic Colonography Compared With Standard Diagnostic Procedures in Detecting Colorectal Neoplasia

NCT00005809
View directory record Official record
Conditions
Colorectal Cancer
Interventions
computed tomography, diagnostic colonoscopy
Procedure
Lead sponsor
American College of Radiology Imaging Network
Network
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
11
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2013 · Synced Sep 16, 2026, 10:45 AM EDT
Terminated Phase 1 Interventional

Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation

NCT05737706
View directory record Official record
Conditions
Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer, Colo-rectal Cancer, Pancreatic Adenocarcinoma
Interventions
MRTX1133
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
14
States / cities
Phoenix, Arizona • New Haven, Connecticut • Lady Lake, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2025 · Synced Sep 16, 2026, 10:45 AM EDT
Terminated Phase 1 Interventional

Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers

NCT04553692
View directory record Official record
Conditions
Solid Tumor, Colorectal Cancer, Non Hodgkin Lymphoma, Sarcoma, Chondrosarcoma, Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia
Interventions
Aplitabart (IGM-8444), FOLFIRI, Bevacizumab (and approved biosimilars), Birinapant, Venetoclax, Gemcitabine, Docetaxel, Azacitidine
Drug
Lead sponsor
IGM Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
37
States / cities
Phoenix, Arizona • Duarte, California • Los Alamitos, California + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2025 · Synced Sep 16, 2026, 10:45 AM EDT
Completed Phase 2 Interventional Results available

Bevacizumab Plus Capecitabine (Xeloda) in Patients With Untreated Metastatic Colorectal Cancer

NCT00203411
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Capecitabine (Xeloda), Bevacizumab
Drug
Lead sponsor
Translational Oncology Research International
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
12
States / cities
Alhambra, California • Bakersfield, California • Fullerton, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2017 · Synced Sep 16, 2026, 10:45 AM EDT
Completed Phase 2 Interventional

DJ-927 as Second-Line Therapy in Treating Patients With Progressive Locally Advanced or Metastatic Colorectal Adenocarcinoma

NCT00080834
View directory record Official record
Conditions
Colorectal Cancer
Interventions
DJ-927
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
2
States / cities
Albuquerque, New Mexico • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 15, 2012 · Synced Sep 16, 2026, 10:45 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

NCT06445062
View directory record Official record
Conditions
Colorectal Cancer, CRC, Pancreatic Ductal Adenocarcinoma, PDAC, Gastrointestinal Cancer, Metastatic Pancreatic Ductal Adenocarcinoma
Interventions
RMC-6236, mFOLFOX6 regimen, bevacizumab, mFOLFIRINOX regimen, cetuximab, gemcitabine, nab-paclitaxel, RMC-9805
Drug
Lead sponsor
Revolution Medicines, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
32
States / cities
Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 16, 2026, 10:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Increasing Engagement With Messages Regarding CRC Screening Among Adults Aged 45-49

NCT05281159
View directory record Official record
Conditions
Colorectal Cancer, Colorectal Neoplasms
Interventions
Risk Information, Risk Information + Action
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
45 Years to 49 Years
Enrollment
20,509 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Westwood, Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 12, 2023 · Synced Sep 16, 2026, 10:45 AM EDT
Active, not recruiting Phase 2 Interventional

Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation

NCT05308446
View directory record Official record
Conditions
Metastatic Colon Adenocarcinoma, Metastatic Rectal Adenocarcinoma, Stage III Colon Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Stage IV Colon Cancer AJCC v8, Stage IV Rectal Cancer AJCC v8, Unresectable Colon Adenocarcinoma, Unresectable Rectal Adenocarcinoma
Interventions
Cetuximab, Encorafenib, Nivolumab
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
282
States / cities
Goodyear, Arizona • Carmichael, California • Dublin, California + 223 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 16, 2026, 10:45 AM EDT
Completed No phase listed Observational

Where Culture Meets Genetics: Exploring Latinas Causal Attributions of Breast and Colon Cancer and Models of Disease Inheritance

NCT02767986
View directory record Official record
Conditions
Colon Cancer, Breast Cancer
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
18 Years to 75 Years · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 2, 2024 · Synced Sep 16, 2026, 10:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Polyp Detection With the EndoRings™: A Randomized Tandem Colonoscopy Study

NCT01955122
View directory record Official record
Conditions
Colon Cancer
Interventions
Tandem Colonoscopy
Device
Lead sponsor
EndoAid
Industry
Eligibility
40 Years to 75 Years
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 5, 2017 · Synced Sep 16, 2026, 10:45 AM EDT
Terminated Phase 1 Interventional

A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

NCT04682431
View directory record Official record
Conditions
Advanced Solid Tumor, Gynecologic Cancer, Breast Cancer, Colorectal Cancer, Gastric Adenocarcinoma, Lung Adenocarcinoma, Pancreatic Cancer, Head and Neck Cancer
Interventions
PY159 Single agent dose level 1, PY159 Single agent dose level 2, PY159 Single agent dose level 3, PY159 Single agent dose level 4, PY159 Single agent dose level 5, PY159 Single agent dose level 6, PY159 Single agent dose level 7, PY159/Pembrolizumab Combination dose level 1, PY159/Pembrolizumab Combination dose level 2, PY159/Pembrolizumab Combination dose level 3, PY159/Pembrolizumab Combination dose level 4, PY159 Single agent dose expansion cohort, PY159/Pembrolizumab Combination dose expansion cohort 1, PY159/Pembrolizumab Combination dose expansion cohort 2, PY159/Pembrolizumab Combination dose expansion cohort 3, PY159/Pembrolizumab Combination dose expansion cohort 4, PY159/Pembrolizumab Combination dose expansion cohort 5, PY159/Pembrolizumab Combination dose expansion cohort 6
Drug
Lead sponsor
Ikena Oncology
Industry
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
17
States / cities
Los Angeles, California • San Francisco, California • Santa Monica, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2024 · Synced Sep 16, 2026, 10:45 AM EDT
Terminated Phase 1 Interventional

A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.

NCT06546553
View directory record Official record
Conditions
Neoplasms, Non-small-cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Colorectal Carcinoma, Ovarian Carcinoma
Interventions
PF-07826390, sasanlimab, SOC (anti-PD-1 + platinum -based chemo)
Drug · Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
8
States / cities
Beverly Hills, California • Fort Myers, Florida • Orlando, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Sep 16, 2026, 10:45 AM EDT
Completed Not applicable Interventional Results available

Information With or Without Numbers For Optimizing Reasoning About Medical Decisions

NCT02477553
View directory record Official record
Conditions
Colorectal Cancer Screening
Interventions
DA - Quantitative, DA - Verbal
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
50 Years to 75 Years
Enrollment
728 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 28, 2019 · Synced Sep 16, 2026, 10:45 AM EDT
Terminated Phase 4 Interventional

Study Comparing Optimized 5-FU Dosing and Standard Dosing in Metastatic Colorectal Cancer Patients Treated With mFOLFOX6

NCT01468623
View directory record Official record
Conditions
Colorectal Cancer, Metastatic
Interventions
Pharmacokinetic 5-FU dose adjustment using OnDose® assay, Standard of care
Other
Lead sponsor
Myriad Genetic Laboratories, Inc.
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
58
States / cities
Birmingham, Alabama • Corona, California • Fountain Valley, California + 55 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2023 · Synced Sep 16, 2026, 10:45 AM EDT
Completed Not applicable Interventional

Improving the Frequency of Colonoscopy in Patients With a Previous Colorectal Polyp

NCT00397969
View directory record Official record
Conditions
Colorectal Cancer, Precancerous Condition
Interventions
counseling intervention, screening colonoscopy
Other · Procedure
Lead sponsor
Harvard Medical School (HMS and HSDM)
Other
Eligibility
21 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Sep 16, 2026, 10:45 AM EDT
Completed No phase listed Observational

Perfusion CT as a Predictor of Treatment Response in Patients With Rectal Cancer

NCT01460641
View directory record Official record
Conditions
Rectal Cancer
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 6, 2018 · Synced Sep 16, 2026, 10:45 AM EDT
Completed Phase 1 Interventional

Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies

NCT03199586
View directory record Official record
Conditions
Breast Cancer, Pancreas Cancer, Prostate Cancer, Lung Cancer, Colon Cancer, Esophagus Cancer, Liver Cancer, Ovary Cancer, Advanced or Metastatic Treatment-refractory Solid Tumor Malignancies
Interventions
NP-G2-044
Drug
Lead sponsor
Novita Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
3
States / cities
Scottsdale, Arizona • Duarte, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 19, 2025 · Synced Sep 16, 2026, 10:45 AM EDT
Completed Not applicable Interventional

Choice Architecture and Mailed Colorectal Cancer Screening Outreach in a Community Health Setting

NCT04711473
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Colonoscopy Only, Choice, FIT Only
Behavioral
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
50 Years to 74 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Pottstown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 12, 2023 · Synced Sep 16, 2026, 10:45 AM EDT
Recruiting Not applicable Interventional

Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS)

NCT06340646
View directory record Official record
Conditions
Cholangiocarcinoma, Multiple Myeloma, Colon Cancer, Rectal Cancer
Interventions
Return of Genetic Results: Biomarker information from cancer cells, Return of Genetic Results: Inherited mutations related to cancer, Return of Genetic Results: Inherited mutations related to other medical issues
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
990 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Sep 16, 2026, 10:45 AM EDT
Recruiting Not applicable Interventional

Histotripsy Plus Chemotherapy vs Chemotherapy Alone for Advanced Colorectal Liver Metastasis

NCT07044362
View directory record Official record
Conditions
Colorectal Cancer, Liver Metastases, Liver Cancer
Interventions
HistoSonics Edison® System, Chemotherapy
Device · Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 16, 2026, 10:45 AM EDT
Recruiting Phase 2 Interventional

BAL/BOT/agenT-797 in pMMR CRC With Liver Metastases

NCT07550088
View directory record Official record
Conditions
Colorectal Cancer Metastatic
Interventions
Balstilimab (BAL), Botensilimab (BOT), agenT-797
Drug
Lead sponsor
Darren Sigal, MD
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 16, 2026, 10:45 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

TVB 2640 for Resectable Colon Cancer Other Resectable Cancers; a Window Trial.

NCT02980029
View directory record Official record
Conditions
Colon Cancer
Interventions
TVB-2640, Placebo
Drug · Other
Lead sponsor
Mark Evers
Other
Eligibility
18 Years to 99 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 21, 2024 · Synced Sep 16, 2026, 10:45 AM EDT
Recruiting Not applicable Interventional

An Informational and Supportive Care Intervention for Patients With Locally Advanced Rectal Cancer

NCT05914766
View directory record Official record
Conditions
Rectal Cancer, Self Efficacy
Interventions
PATHWAYS, Enhanced usual care
Behavioral · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 17, 2025 · Synced Sep 16, 2026, 10:45 AM EDT
Completed Phase 1Phase 2 Interventional

Combination Chemotherapy and Oblimersen in Treating Patients With Advanced Colorectal Cancer

NCT00055822
View directory record Official record
Conditions
Colorectal Cancer
Interventions
oblimersen sodium, fluorouracil, leucovorin calcium, oxaliplatin
Biological · Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 3, 2012 · Synced Sep 16, 2026, 10:45 AM EDT